Journal of ophthalmology · 2026
Effect of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Qing, Li Yuan, Jiang Yalin, Sun Xincheng
Аннотация
PURPOSE: Purpose: To present and evaluate the effect of a novel technique, 25-gauge (G) needle-assisted phacoemulsification, to remove dislocated intravitreal lens nuclei.
METHODS: Methods: Nine eyes of nine patients with dislocated intravitreal lens nuclei who underwent 23-G pars plana vitrectomy (PPV) and 25-G needle-assisted phacoemulsification between July 2022 and September 2024 were included in this study. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and corneal endothelial cell count (CECC) were statistically analysed both preoperatively and postoperatively. The intraoperative and postoperative complications were evaluated. A minimum follow-up of 6 months was completed for all eyes.
RESULTS: Results: All nine eyes of nine patients were successfully treated with 23-G PPV and 25-G needle-assisted phacoemulsification and postoperatively followed up for 6-13 months. BCVA improved significantly (p < 0.05) in all patients, and postoperative IOP was 16.0 ± 1.73 mmHg, remaining stable within the normal range. Although statistical differences were observed between preoperative and final follow-up, the loss rate of CECC was within a tolerable range. No intraoperative and postoperative complications, such as iatrogenic retinal tears or vitreous haemorrhage, were observed.
CONCLUSION: Conclusion: The 25-G needle-assisted phacoemulsification is a safe and efficient alternative for removing dislocated intravitreal lens nuclei. Trial Registration: ClinicalTrials.gov identifier: NCT06709378.
METHODS: Methods: Nine eyes of nine patients with dislocated intravitreal lens nuclei who underwent 23-G pars plana vitrectomy (PPV) and 25-G needle-assisted phacoemulsification between July 2022 and September 2024 were included in this study. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and corneal endothelial cell count (CECC) were statistically analysed both preoperatively and postoperatively. The intraoperative and postoperative complications were evaluated. A minimum follow-up of 6 months was completed for all eyes.
RESULTS: Results: All nine eyes of nine patients were successfully treated with 23-G PPV and 25-G needle-assisted phacoemulsification and postoperatively followed up for 6-13 months. BCVA improved significantly (p < 0.05) in all patients, and postoperative IOP was 16.0 ± 1.73 mmHg, remaining stable within the normal range. Although statistical differences were observed between preoperative and final follow-up, the loss rate of CECC was within a tolerable range. No intraoperative and postoperative complications, such as iatrogenic retinal tears or vitreous haemorrhage, were observed.
CONCLUSION: Conclusion: The 25-G needle-assisted phacoemulsification is a safe and efficient alternative for removing dislocated intravitreal lens nuclei. Trial Registration: ClinicalTrials.gov identifier: NCT06709378.